Get started
Author

Andrew Belch

International uniform response criteria for multiple myeloma
2006 · B G M Durie, J-L Harousseau, et al. · Leukemia · 2,637
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
2015 · Antonio Palumbo, Sara Bringhen, et al. · Blood · 777
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
2011 · S K Kumar, J H Lee, et al. · Leukemia · 720
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
2016 · Saad Z. Usmani, Brendan M. Weiss, et al. · Blood · 406
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
2014 · Paul G. Richardson, David S. Siegel, et al. · Blood · 381
Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double‐blind, placebo‐controlled study
2003 · Michael Hedenus, Magnus Adriansson, et al. · British Journal of Haematology · 326
PDF
Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group
2003 · C. Tom Kouroukis, Andrew Belch, et al. · Journal of Clinical Oncology · 277
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
2017 · Thierry Facon, Meletios A. Dimopoulos, et al. · Blood · 271
PDF
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
2019 · Thierry Facon, Meletios A. Dimopoulos, et al. · Leukemia · 239
PDF
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials
2020 · Saad Z Usmani, Hareth Nahi, et al. · The Lancet Haematology · 109
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma
2009 · Edward A. Stadtmauer, Donna M. Weber, et al. · European Journal Of Haematology · 106
PDF
Oral complications of acute leukemia: Prophylactic impact of a chlorhexidine mouth rinse regimen
1985 · Wm.T. McGaw, A. Belch · Oral Surgery Oral Medicine Oral Pathology · 106
Long-Term Survival Analysis of the North American Intergroup Study C9011 Comparing Fludarabine (F) and Chlorambucil (C) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL).
2009 · Kanti R. Rai, Bercedis L. Peterson, et al. · Blood · 45
Erratum: International uniform response criteria for multiple myeloma
2006 · B G M Durie, J-L Harousseau, et al. · Leukemia · 43
PDF
Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation
2004 · Brian G M Durie, Robert A Kyle, et al. · The Hematology Journal · 42
An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkins lymphoma.
2003 · Robert Marcus, Kevin Imrie, et al. · Ghent University Academic Bibliography (Ghent University) · 41
The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011)
2012 · Melhem Solh, Kanti R. Rai, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 38
Phase II study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius).
2015 · Sagar Lonial, Brendan M. Weiss, et al. · Journal of Clinical Oncology · 35
Phase II Trial of Bortezomib in Mantle Cell Lymphoma.
2004 · Andrew Belch, C. Tom Kouroukis, et al. · Blood · 34
Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma
2018 · Xu Steven Xu, Meletios A. Dimopoulos, et al. · Advances in Therapy · 31
PDF
Origin of leukemic relapse after bone marrow transplantation detected by restriction fragment length polymorphism.
1985 · M D Minden, H A Messner, et al. · Journal of Clinical Investigation · 31
PDF
Bortezomib retreatment for relapsed and refractory multiple myeloma in real‐world clinical practice
2018 · Cyrille Hulin, Javier de la Rubia, et al. · Health Science Reports · 28
PDF
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux
2016 · Saad Z Usmani, Meletios A Dimopoulos, et al. · Blood · 28
Activity of lenalidomide in a phase II trial for T-cell lymphoma: Report on the first 24 cases
2009 · G. S. Dueck, N. Chua, et al. · Journal of Clinical Oncology · 28
Hemolysis in mice treated with deoxycoformycin, am inhibitor of adenosine deaminase
1980 · Camila M. Smith, Andrew Belch, et al. · Biochemical Pharmacology · 27
Works count: 60
Citation count: 7,090
H-index: 25
I10-index: 38
Year
Topic
Type